DelveInsight's Interleukin-23 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Indiana company says new drone regulations will speed improvements to package delivery security for Americans INDIANAPOLIS, IN / ACCESS Newswire / August 6, 2025 / Arrive AI (NASDAQ:ARAI), an ...

Gryphon Stockholder Voting Has Commenced for Special Meeting to Be Held on August 27, 2025 Gryphon’s Board of Directors ...

Oekoboiler Swiss AG, known for leading in Switzerland’s manufacturing sector, has announced its new way of offering ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Global Fintech Doubles Down on ESG Commitments to Build a More Sustainable and Inclusive Future BOULDER, CO / ACCESS Newswire ...

MISSISSAUGA, ONTARIO / ACCESS Newswire / August 6, 2025 / Consumer Choice Award is pleased to announce the 2025 award recipients in the Peel Region. These businesses have been meticulously selected ...

LAFAYETTE, LA / ACCESS Newswire / August 6, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), an ...

WHITBY, ON / ACCESS Newswire / August 6, 2025 / Consumer Choice Award is pleased to announce the 2025 award recipients in the ...

Key Points GAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13. GAAP revenue of $5.5 million in Q2 2025 missed expectations by 26%. Advanced key clinical programs, with first U.S.

Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New Drug Application to the U.S. FDA for icotrokinra, an oral peptide ...

Icotrokinra was jointly discovered and is being developed under a license and collaboration agreement between Protagonist and Johnson & Johnson.